Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Actuate TherapeuticsACTU -1.96%14 3-Year EPS without NRI Growth Rate is 7.60% as of Mar. 2026, which is at its 10-year median of 7.60. GuruFocus rates ACTU with a GF Score™ of 14/100. Among 1,160 Biotechnology companies, Actuate Therapeutics ranks worse than 60.95% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 7.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 4 years, the highest 3-Year average EPS without NRI Growth Rate of Actuate Therapeutics was 7.60% per year. The lowest was 7.60% per year. And the median was 7.60% per year.
Actuate Therapeutics (NAS:ACTU) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Actuate Therapeutics 3-Year EPS without NRI Growth Rate Related Terms
ACTU vs KYNB, IGC, PLRZ: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Actuate Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Actuate Therapeutics 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Actuate Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Actuate Therapeutics's 3-Year EPS without NRI Growth Rate falls into.
Actuate Therapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 7.60% mean?
Actuate Therapeutics (ACTU) has a 3-Year EPS without NRI Growth Rate of 7.60% as of Mar. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Actuate Therapeutics and its competitors. This is near median its historical median of 7.60. Over the past decade, Actuate Therapeutics' 3-Year EPS without NRI Growth Rate has ranged from 7.60 to 7.60. According to the industry distribution chart, Actuate Therapeutics ranks #707 out of 1160 companies in the Biotechnology industry, placing it in the top 60.9%.
Is Actuate Therapeutics' 3-Year EPS without NRI Growth Rate too high?
Actuate Therapeutics' current 3-Year EPS without NRI Growth Rate of 7.60% is near median its 10-year median of 7.60. Over the past 10 years, this metric has ranged from a low of 7.60 to a high of 7.60. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. Actuate Therapeutics' value of 7.60% is 53.1% below this industry median. Based on the distribution chart, Actuate Therapeutics ranks #707 out of 1160 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Actuate Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Actuate Therapeutics' 3-Year EPS without NRI Growth Rate compare to KYNB and IGC?
According to the Biotechnology industry distribution chart, Actuate Therapeutics ranks #707 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This places Actuate Therapeutics in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.20. Actuate Therapeutics' value of 7.60% is 53.1% below this benchmark. Historically, Actuate Therapeutics' own 3-Year EPS without NRI Growth Rate has ranged from 7.60 to 7.60 over the past decade. While the company's 10-year median is 7.60 vs. the industry median of 16.20, Actuate Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Actuate Therapeutics's current 3-Year EPS without NRI Growth Rate of 7.60% is 53.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Actuate Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Actuate Therapeutics's current 3-Year EPS without NRI Growth Rate is 7.60%, which is near median its own 10-year median of 7.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actuate Therapeutics stock overvalued right now?
Actuate Therapeutics (ACTU) has a current 3-Year EPS without NRI Growth Rate of 7.60%. The current 3-Year EPS without NRI Growth Rate is 7.60%, which is near median its 10-year median of 7.60 and 53.1% below the Biotechnology industry median of 16.20. Actuate Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Actuate Therapeutics (ACTU), the current 3-Year EPS without NRI Growth Rate is 7.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
14GF Score
Get the complete analysis for ACTU
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACTU has been successfully added to your 
